The final trading week of the year showcased the extreme volatility of biotech investments, with Mesoblast shares soaring on FDA approval and Percheron Therapeutics plummeting after a failed trial.
In the final trading week of the year, we saw examples of both the windfall gains and wipe-out losses that can occur from investing in biotechnology companies developing next-generation drug treatments. For the long-suffering investors in ASX-listed Mesoblast, Christmas came early, as news of the US Food and Drug Administration’s approval for its Ryoncil therapy to be used in children afflicted with a rare but devastating disease sent shares rocketing over 50 percent.
It was a milestone 20 years in the making for which shareholders endured a roller coaster of rejections, delays and capital raisings to realise. In the past year, Mesoblast’s shares have risen from 30¢ to $3, a significant gain for some, but for others who invested during the peaks of over $9, a significant capital burner. In the very same week, investors in Percheron Therapeutics were left with nothing but a large tax write-off for Christmas when shares fell over 90 percent on news that its experimental muscular dystrophy drug failed to show efficacy in trials. These two contrasting outcomes illustrate the binary nature of the industry for investors. The earlier you invest, the greater the gains should the drug succeed, but higher the chance of failure.“I’ve seen many disasters over the years – sadly many, many more than the handful of success stories,” says Dean Fergie, Portfolio Manager at Cyan Investment Management.Investing later in development process is one way to for investors to minimise risk, but there exists a trade-off in returns, with the likelihood of success already factored into the share price. Others choose to invest betting that one day there will be a takeover by ‘Big Pharma’ players like Pfizer, Merck, or Johnson & Johnso
BIOTECHNOLOGY INVESTMENTS RISK RETURNS PHARMACEUTICALS
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
‘Hong Kong without the view’: High-rise push dubbed high risk for city’s futureMelbourne’s suburbs will be less desirable if housing comes at the expense of heritage, the Royal Historical Society of Victoria has warned.
Read more »
High profile, high risk: could Mandelson help tame Donald Trump?Labour veteran Peter Mandelson is the first political appointment as ambassador to Washington in 50 years
Read more »
Israel condemns Australia’s UN ‘flip flop’, says it rewards terrorismIn it’s most damning statement yet, Israel’s President Benjamin Netanyahu’s office made clear the decision to promote Palestinian statehood was seen as a betrayal.
Read more »
Israel condemns Australia’s UN ‘flip flop’, says it rewards terrorismIn it’s most damning statement yet, Israel’s President Benjamin Netanyahu’s office made clear the decision to promote Palestinian statehood was seen as a betrayal.
Read more »
Young people travel hacking with credit card rewards points are failing to clear their debtsA survey finds more than half of people aged 18 to 29 with a credit card sign up solely to earn travel rewards points, but 60 per cent are struggling to clear their debts each month.
Read more »
Star import Sam Billings tips Big Bash League to reap rewards from contract shake-up7NEWS brings you the latest local news from Australia and around the world. Stay up to date with all of the breaking sport, politics, entertainment, finance, weather and business headlines. Today's news, live updates & all the latest breaking stories from 7NEWS.
Read more »